Stock CYTO ALTAMIRA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

News Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Market Closed - Nasdaq
Other stock markets
 03:59:50 2024-07-12 pm EDT 		5-day change 1st Jan Change
1.31 USD -0.76% Intraday chart for Altamira Therapeutics +2.34% -62.36%
Jun. 20 Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management CI
May. 16 Altamira Therapeutics Ltd. Elects Dominik Lysek as Member of Board of Directors CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
AQ
Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
CI
Altamira Therapeutics Provides Business Update
AQ
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
AQ
Altamira Therapeutics Ltd. Elects Dominik Lysek as Member of Board of Directors
CI
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
AQ
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
CI
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
AQ
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
CI
Altamira Therapeutics : Notice of the Annual General Meeting of Shareholders of Altamira Therapeutics Ltd. (the “Company”) to be held on May 16, 2024 - Form 6-K
PU
Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
AQ
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
AQ
Sector Update: Health Care Stocks Decline Late Afternoon
MT
Top Midday Gainers
MT
Sector Update: Health Care Stocks Softer in Afternoon Trading
MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge
MT
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
AQ
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. CYTO Stock
  5. News Altamira Therapeutics